Symptoms and their Relationship to Disability Following Treatment for Lower Extremity Tumours by Davis, Aileen M. et al.
Sarcoma (1999) 3, 73± 77
ORIGINAL ARTICLE
Symptoms and their relationship to disability following treatment for
lower extremity tumours
AILEEN M. DAVIS, SAJEEVAN PUNNIYAMOORTHY, ANTHONY M. GRIFFIN,
JAY S.WUNDER & ROBERT S. BELL
The University Musculoskeletal Oncology Unit, Mount Sinai Hospital and The University of Toronto,Toronto, Canada
Abstract
Purpose. The aims of this study were to describe the symptoms experienced by patients in the ® rst year following treatment
for lower extremity sarcoma by limb conservation and to describe the relationship between symptoms and physical disability.
Subjects. Eighty consecutive patients treated for primary bone or soft tissue sarcoma (STS) of the lower limb who were
treated with limb preservation surgery.
Methods. Subjects were evaluated by questionnaire at 6 weeks, and 3, 6, and 12 months post surgery. They identi® ed
whether they experienced any of the following symptoms: pain, stiffness, fatigue, weakness, limited range of motion, or
swelling.The Toronto Extremity Salvage Score (TESS), a measure of physical disability, was also completed. Frequency of
symptoms over time was calculated and change was evaluated using the Cochrane test. The relationship of symptoms to
disability was analyzed with regression methods.
Results. The mean age was 43.0, SD=20.4 with a gender ratio of 1:1.There were 38 bone tumours and 42 STS.The most
frequently reported symptoms were: stiffness 48 (60%), weakness 41 (51%), fatigue 26 (33%), and pain 25 (31%) at 6
weeks. Stiffness and fatigue decreased and plateaued by 3 months. Complaints of weakness and pain continued to decrease
over time. At 6 weeks, pain, stiffness, weakness and limited motion predicted disability in both univariate and multivariate
analyses. At 12 months, pain, stiffness, fatigue, weakness and limited motion were signi® cant predictors of the TESS in
univariate analysis with only pain, stiffness and limited motion signi® cant predictors in the multivariate model.
Discussion. Pain, stiffness, fatigue, weakness and limited motion are common symptoms with stiffness and weakness
decreasing signi® cantly over time.The symptoms predictive of disability differ between the acute and late phases of recovery.
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Introduction
Over the past two decades, limb conservation surgery
for patients with extremity sarcoma has become the
accepted standard of treatment. This standard has
been attainable mainly due to the advent of modern
imaging techniques and advances in surgical recon-
structive techniques.The outcomes of patients treated
by limb conservation have been reported in terms of
survival and local control with few studies addressing
the symptoms and disability experienced by patients
following treatment.
1± 4 Of these published studies
reporting morbidity outcomes, many include patients
treated in the 1970s and early 1980s, such that the
outcomes related to treatment morbidity do not reflect
current advances in treatment.
1± 3 The aims of the
current study were: to describe the symptoms
experienced by patients in the ® rst year following
treatment by limb conservation for lower extremity
sarcoma; to evaluate how the reported symptoms
change over time; and to describe the relationship
between symptoms and physical disability.
Methods
From June 1994 to July 1995, 97 consecutive,
consenting patients with primary bone or soft tissue
(STS) sarcoma of the lower extremity were entered
in the study. All patients were treated by limb
conservation surgery. Use of adjuvant therapy, radia-
tion or chemotherapy, was determined by the multi-
disciplinary team on a case by case basis. Adjuvant
radiotherapy for soft tissue sarcoma was delivered as
previously described by our group
5and chemotherapy
for patients with bone tumours varied according to
the tumour histology. Patients presenting with
metastatic disease, or who could not complete the
questionnaires for reasons of language or cognition
were excluded from the study.
Symptoms and the disability experienced by
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and 3, 6 and 12 months post-operatively. Previous
pilot interviews
6 identi® ed that patients thought that
pain, stiffness, fatigue, limited range of motion, weak-
ness, swelling and abnormal sensation were important
symptoms. Consequently, subjects were asked to
indicate all symptoms that they experienced from the
above list and they were also able to add additional
symptoms. Physical disability was evaluated by the
patient using the Toronto Extremity Salvage Score
(TESS).
7,8The TESS is a reliable and valid measure
of physical disability developed for the extremity
sarcoma population in which patients rate their ability
to perform routine daily activities.
7
Symptom data were analyzed by frequency at each
point in time and change over time was evaluated
graphically and using the Cochrane test.The relation-
ship of symptoms to disability as measured by the
TESS was evaluated in the immediate post-operative
period (6 weeks) and then at 12 months post surgery
when most patients had reached their maximal level
of functioning.This relationship was evaluated using
regression methods.
Of the 97 consecutive patients for whom functional
outcome (TESS) data and symptoms data was avail-
able, only 80 had symptom data for all the time
points.The data from these 80 subjects with complete
data at all evaluation times formed the sample for
analysis. The 17 subjects excluded from the analysis
did not differ on any descriptive variables or their
outcome from the sample of 80 (data not shown).
Results
The subjects had a mean age of 43 years (± 20) and
41 were male.The sample included 38 subjects with
primary bone tumours and the remaining 42 had
primary soft tissue sarcomas. As anticipated in lower
extremity musculoskeletal tumour patients, most
tumours were proximal, speci® cally with 36 located
in the area of the pelvis and hip, 35 at the knee and
nine in the distal leg, foot and ankle. Of the bone
tumour subjects, 11 were treated with adjuvant
chemotherapy and 35 of the soft tissue sarcoma
subjects received adjuvant radiotherapy.
At 6 weeks post surgery, pain (31%), stiffness
(60%), fatigue (33%), weakness (51%) and limited
range of motion (29%), were common symptoms
experienced by patients (Table 1).With the exception
of complaints of pain and swelling, the frequency of
these symptoms decreased as the interval of time
following surgery increased. Complaints of pain were
relatively constant in frequency across patients until
6 months post surgery and then declined. Swelling
was present in approximately 10% of cases at a given
point in time.While appearing constant in frequency
across time, the numbers actually re¯ ect different
subjects reporting swelling at a single point in time
for half the cases. For instance, only a small number
of cases (n=8), showed signs of swelling 6 weeks after
surgery, and of these, less than half (n=3) showed
signs of swelling at other time points. Hence, the
number of subjects with persistent swelling across
time was very small (3 of 80). Of particular note is
the increasing frequency of subjects who have no
symptom complaints in the year post surgery. By 12
months post-operatively, approximately 25% of
subjects report no symptoms limiting their daily activi-
ties.
Considering that patients may not experience a
single symptom in isolation, the data were analyzed
to determine whether there were consistent symptom
complexes reported. Speci® cally, we a priori evalu-
ated the frequencies of three combinants of
symptoms: (1) stiffness and weakness; (2) pain, stiff-
ness and weakness; and (3) stiffness and limited range
of motion. However, there did not appear to be
consistent symptom complexes as the frequencies
were 5% or less at all times for this patient sample.
The change in symptoms over time is shown graphi-
cally in Fig. 1a,b. There appear to be two patterns of
symptom variation over time following treatment for
lower extremity tumours. First, as shown in Fig. 1a,
stiffness, fatigue and limited ROM show a plateau-
type pattern. Stiffness is present to a great extent
initially (60% of patients at 6 weeks) but then plateaus
to approximately 45% of patients. Fatigue also
plateaus after 3 months with approximately 23%
(n=18) of patients subsequently experiencing this
symptom.The data suggest that complaints of weak-
ness and pain, however, do not plateau. Both pain
and weakness are constant through 3 months and
decline progressively through 6 and 12 months post
surgery (Fig. 1b).
Statistical analysis of the change in frequency of
symptoms over time using the Cochrane test and
then McNemar’s test post hoc to determine the specific
Table 1. Frequency of symptoms in 80 subjects with lower extremity tumours treated by limb preservation
Symptom 6 weeks (%) 3 months (%) 6 months (%) 12 months (%)
No symptoms 7 (9) 12 (15) 17 (21) 21 (26)
Pain 25 (31) 28 (35) 21 (26) 16 (20)
Stiffness 48 (60) 37 (46) 35 (44) 34 (43)
Fatigue 26 (33) 17 (21) 19 (24) 19 (24)
Weakness 41 (51) 40 (50) 29 (36) 23 (28)
ROM 23 (29) 13 (16) 13 (16) 12 (15)
Swelling 8 (10) 5 (6) 8 (10) 6 (8)
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data presented graphically. There is no statistically
signi® cant difference (p>0.05) in the frequency of
complaints of pain, fatigue or swelling over time.
There was a trend towards decreasing stiffness from
6 weeks post surgery to 6 months (p=0.04). There
was also a trend towards decreasing complaints of
weakness from 3 to 6 months (p=0.04), with a more
signi® cant decrease in complaints of weakness by 12
months from any of the earlier times (p values ranging
from 0.004 to 0.002). Decreasing complaints of
limitation of range of motion were signi® cant for all
times compared to 6 week (p-values ranging from
0.03 to 0.01).
Physical disability was evaluated by theTESS. At 6
weeks post surgery, the mean TESS score was 64.3
(SD=23.9). Correlating the presence of each of pain,
stiffness, fatigue, weakness, limited ROM or swelling
with the TESS score, the correlation coefficients
ranged from ± 0.31 to ± 0.39 (Spearman’s r ) indicating
that the presence of the speci® c symptom resulted in
lowerTESS scores. All correlations were significantly
different from zero. At 12 months, the mean TESS
score was 83.9 (SD=15.8). Again the presence or
absence of each symptom was correlated with the
TESS score with the correlation coefficients ranging
from ± 0.39 to ± 0.51.All correlations were significantly
different than zero.
Regression analysis controlling for whether the
patient had a bone or soft tissue sarcoma was used to
evaluate the relationship of symptoms to physical
disability as measured by the TESS. Table 2 shows
that, at 6 weeks, complaints of pain, stiffness, weak-
ness and limited ROM are signi® cant predictors of
disability in both univariate and multivariate analyses.
In multivariate analysis, these symptoms explained
40% of the variance in the TESS score after control-
ling for whether the subject was treated for a bone or
soft tissue tumour. At 12 months post surgery, pain,
stiffness, fatigue, weakness, limited ROM were
signi® cant predictors of the TESS in univariate
analysis. However, fatigue and weakness lost their
Figure 1 Frequency of symptoms over time following limb preservation surgery for lower extremity sarcoma. (a) Symptoms with a
plateau in frequency over time. (b) Symptoms decreasing in frequency over time.
Symptoms and disability in lower extremity sarcoma 75signi® cance in the multivariate model. After control-
ling for bone versus soft tissue tumour, pain, stiff-
ness, and limited ROM explained 51% of the variation
in the TESS score of patients.
Discussion
This study has con® rmed that symptoms are an
important outcome experienced by patients who
undergo limb preservation surgery for extremity
tumours. At least 80% of patients continue to experi-
ence some symptoms at 1 year post surgery. The
symptoms most frequently reported include: stiffness
(60%), weakness (51%), fatigue (33%), pain (31%),
limited ROM (29%) and swelling (10%).These ® nd-
ings are similar to work of other authors who reported
pain, swelling and weakness in soft tissue sarcoma
patients
1± 4 and pain and weakness in bone tumour
patients.
To our knowledge, the current study is the ® rst to
evaluate how symptoms change over time. Two
patterns were identi® ed, one that shows that stiffness,
fatigue and limited ROM remain quite constant after
3 months and another that suggests that pain and
weakness continue to decrease in frequency 6 and 12
months post treatment. These patterns re¯ ect tissue
healing physiology. Soft tissue healing by scarring
occurs in the ® rst 3 to 6 weeks under normal condi-
tions, but healing is prolonged in the face of
radiotherapy and chemotherapy. Consequently, the
® rst 3 months following surgery is the period during
which rehabilitation is directed towards improving
soft tissue lengthening and gaining joint motion by
breaking soft tissue adhesions. Although strengthening
is important in the early phases of rehabilitation, the
most signi® cant gains are observed later when
strengthening can occur through the functional range
of a joint. Furthermore, strengthening is more
functionally based in the later stages of recovery as
activity and endurance are emphasized.
The persistence of pain and weakness from 6 weeks
to 3 months may also result from patients attempting
more activities as they move further from their surgery.
Similarly, patients may report feeling weaker due
to increased exertion. It is possible that patients cannot
perform as many physical tasks as they attempt to do
and therefore report weakness.
As noted above, the plateau in stiffness and ROM
can be explained based on an understanding of tissue
healing. However, the plateau in complaints of fatigue
from 3 months is somewhat surprising. Fatigue was
experienced by 33% of subjects at 6 weeks and at 3, 6
and 12 months reduced to approximately 23%. We
would have anticipated that fatigue would have
decreased as patients moved further from their treat-
ment and improved their endurance. However, work in
other cancers suggests that ongoing fatigue is a
phenomenon associated with the cancer diagnosis.
Speci® cally,in breast cancer,numerous authors
9± 12have
found that fatigue is a frequent and persistent symptom.
The relationship between the presence of symptoms
and the level of patient reported physical disability
suggests that these two phenomena are moderately
related with correlations in the range of magnitude of
0.30± 0.50. The presence of symptoms accounts for
up to 50% of the variance in the disability scores
reported by patients in this sample. Although the
impact of symptoms on physical disability has not
previously been reported in the sarcoma population,
work by Rigby et al.
13 in arthritic populations and
McCarthy et al.
14with injured workers would support
these ® ndings.
This study is the ® rst to evaluate the trajectory of
symptoms experienced by patients who undergo limb
preservation for lower extremity sarcoma and the first
to attempt to understand the relationship of these
symptoms to the ability of patients to continue to
perform their daily activities. Previous authors
1± 4have
reported symptoms experienced by patients at a single
point in time but many of these studies do not reflect
current surgical or adjuvant therapy techniques.The
recent trend in evaluating patient outcomes as a
measure of treatment effectiveness has emphasized
evaluation of functional status and quality of life. It is
important that we recognize the component outcomes
that re¯ ect patient’s status and how these outcomes
relate to each other in order that new treatment
interventions can be rigorously evaluated.
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Table 2. Symptoms as a predictor of physical disability as measured by the TESS
P-value P-value
6 Weeks 12 Months
Symptom Univariate Multivariate Univariate Multivariate
Pain 0.000 0.028 0.000 0.001
Stiffness 0.000 0.018 0.000 0.000
Fatigue N/S N/S 0.000 N/S
Weakness 0.000 0.028 0.000 N/S
ROM 0.004 0.019 0.000 0.000
Swelling N/S N/S N/S N/S
R
2 (variation in TESS explained) N/A 0.40 N/A 0.51
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